ImmunityBio, Inc. — Director's Dealing 2024

Feb 3, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ImmunityBio, Inc. (IBRX)
CIK: 0001326110
Period of Report: 2024-01-31

Reporting Person: Simon Barry J. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-01-31	Common Stock	M	57200	—	Acquired	3145855	Direct
2024-01-31	Common Stock	F	22094	$3.36	Disposed	3123761	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-01-31	Restricted Stock Units	$	M	57200	Disposed		Common Stock (57200)	Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

F2: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 57,199 of the RSUs subject to the award vested on September 1, 2023 and 57,200 of the RSUs subject to the award vested on January 31, 2024.